• F Hoffmann-La Roche – Kinarus possesses worldwide rights to pamapimod in all therapeutic indications licensed from F. Hoffmann La Roche. Pamapimod is a highly-selective inhibitor of p38 mitogen-activated protein kinase (p38 MAPK) that has advanced through Phase 2 clinical development.

  • Ventac Partners – Kinarus collaborates with Ventac Partners, experts in business development, financing and partnering strategies in the biotechnology industry.

Cookies make it easier for us to provide you with our services. With the usage of our services you permit us to use cookies.
Ok